Ultra-accelerated TMS + NRX-101 for Depression

(SPARC-LI Trial)

This trial tests a new approach for treating moderate to severe depression. It combines a medication called NRX-101 with a special type of brain stimulation known as Theta Burst Stimulation (TMS) to determine its effectiveness in improving symptoms. The trial aims to assess the safety and impact of this combination over a six-week period. Individuals experiencing significant depression that affects daily life may be suitable candidates for this trial. As an Early Phase 1 trial, this research seeks to understand how the treatment works in people, providing participants the opportunity to be among the first to receive this innovative treatment.

Previous studies have shown that NRX-101, a combination of D-cycloserine and lurasidone, is safe and does not cause serious treatment-related side effects. Patients reported feeling better, with manageable side effects.

For the other part of the treatment, transcranial magnetic stimulation (TMS) is generally safe and well-tolerated. Most people experience only mild side effects, such as short-lasting headaches. Serious risks, like seizures, are very rare with TMS.

Most treatments for depression rely on medications like SSRIs or SNRIs, which can take several weeks to work. But the combination of ultra-accelerated Transcranial Magnetic Stimulation (TMS) and NRX-101 offers a unique approach. NRX-101 is designed to work faster, potentially providing relief in just days by using a new mechanism that targets glutamate pathways in the brain, rather than the usual serotonin system. Additionally, TMS is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain, which may enhance the effects of NRX-101. Researchers are excited about this treatment because it offers a fresh hope for people who haven't responded well to traditional antidepressants.

Research has shown that NRX-101, a combination of D-cycloserine and lurasidone, may help treat depression. Studies have found that this combination works better than lurasidone alone in preventing the return of depression symptoms. Specifically, patients in those studies experienced significant improvements in their depression and reported fewer suicidal thoughts.